U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Recurrent Moderate-Severe Chronic Graft Versus Host Disease

MedGen UID:
1710926
•Concept ID:
C5237056
•
Disease or Syndrome

Definition

The reemergence of moderate-severe chronic graft versus host disease after a period of remission. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRecurrent Moderate-Severe Chronic Graft Versus Host Disease

Professional guidelines

PubMed

Prophylactic donor lymphocyte infusion after haploidentical hematopoietic cell transplantation and post-transplant cyclophosphamide for treatment of high-risk myeloid neoplasms in children: A retrospective study.
Qi SS, Chen Z, Du Y, Sun M, Wang Z, Long F, Luo L, Xiong H
Pediatr Blood Cancer 2023 Nov;70(11):e30659. Epub 2023 Sep 5 doi: 10.1002/pbc.30659. PMID: 37669234
Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse.
Lee SJ, Klein JP, Barrett AJ, Ringden O, Antin JH, Cahn JY, Carabasi MH, Gale RP, Giralt S, Hale GA, Ilhan O, McCarthy PL, Socie G, Verdonck LF, Weisdorf DJ, Horowitz MM
Blood 2002 Jul 15;100(2):406-14. doi: 10.1182/blood.v100.2.406. PMID: 12091329

Recent clinical studies

Etiology

Ikaros expression is associated with an increased risk of chronic graft-versus-host disease.
Pereira AD, de Molla VC, Fonseca ARBM, Tucunduva L, Novis Y, Pires MS, Popi AF, Arrais-Rodrigues CA
Sci Rep 2023 May 25;13(1):8458. doi: 10.1038/s41598-023-35609-3. PMID: 37231055Free PMC Article
Post-transplant cyclophosphamide as sole GHVD prophylaxis after matched reduced-intensity conditioning allotransplant.
Bourgeois AL, Jullien M, Garnier A, Peterlin P, Béné MC, Guillaume T, Chevallier P
Clin Transl Med 2023 Apr;13(4):e1242. doi: 10.1002/ctm2.1242. PMID: 37140099Free PMC Article
Low-dose antithymocyte globulin inhibits chronic graft-versus-host disease in peripheral blood stem cell transplantation from unrelated donors.
Shiratori S, Sugita J, Fuji S, Aoki J, Sawa M, Ozawa Y, Hashimoto D, Matsuoka KI, Imada K, Doki N, Ashida T, Ueda Y, Tanaka M, Sawayama Y, Ichinohe T, Terakura S, Morishima S, Atsuta Y, Fukuda T, Teshima T
Bone Marrow Transplant 2021 Sep;56(9):2231-2240. Epub 2021 May 7 doi: 10.1038/s41409-021-01314-w. PMID: 33963304
High-Dose Cyclophosphamide and Tacrolimus as Graft-versus-Host Disease Prophylaxis for Matched and Mismatched Unrelated Donor Transplantation.
Pedraza A, Jorge S, Suárez-Lledó M, Pereira A, Gutiérrez-García G, Fernández-Avilés F, Rosiñol L, Llobet N, Solano T, Urbano-Ispízua Á, Rovira M, Martínez C
Transplant Cell Ther 2021 Jul;27(7):619.e1-619.e8. Epub 2021 Mar 25 doi: 10.1016/j.jtct.2021.03.022. PMID: 33895157
Current Graft-versus-Host Disease-Free, Relapse-Free Survival: A Dynamic Endpoint to Better Define Efficacy after Allogenic Transplant.
Solomon SR, Sizemore C, Zhang X, Ridgeway M, Solh M, Morris LE, Holland HK, Bashey A
Biol Blood Marrow Transplant 2017 Jul;23(7):1208-1214. Epub 2017 Apr 5 doi: 10.1016/j.bbmt.2017.02.022. PMID: 28390985

Diagnosis

Azacitidine, lenalidomide and donor lymphocyte infusions for relapse of myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia after allogeneic transplant: the Azalena-Trial.
Schroeder T, Stelljes M, Christopeit M, Esseling E, Scheid C, Mikesch JH, Rautenberg C, Jäger P, Cadeddu RP, Drusenheimer N, Holtick U, Klein S, Trenschel R, Haas R, Germing U, Kröger N, Kobbe G
Haematologica 2023 Nov 1;108(11):3001-3010. doi: 10.3324/haematol.2022.282570. PMID: 37259567Free PMC Article
Haploidentical bone marrow transplants with post transplant cyclophosphamide on day + 3 + 5: The Genova protocol.
Raiola AM, Angelucci E, Sica S, Bacigalupo A
Blood Rev 2023 Nov;62:101031. Epub 2022 Nov 11 doi: 10.1016/j.blre.2022.101031. PMID: 36435691
Age is no barrier for adults undergoing HCT for AML in CR1: contemporary CIBMTR analysis.
Maakaron JE, Zhang MJ, Chen K, Abhyankar S, Bhatt VR, Chhabra S, El Jurdi N, Farag SS, He F, Juckett M, de Lima M, Majhail N, van der Poel M, Saad A, Savani B, Ustun C, Waller EK, Litzow M, Kebriaei P, Hourigan CS, Saber W, Weisdorf D
Bone Marrow Transplant 2022 Jun;57(6):911-917. Epub 2022 Apr 2 doi: 10.1038/s41409-022-01650-5. PMID: 35368040Free PMC Article
Triple post transplant cyclophosphamide (PTCY) based GVHD prophylaxis: HLA matched versus HLA haploidentical transplants.
Galli E, Metafuni E, Giammarco S, Limongiello MA, Innocenti I, Autore F, Laurenti L, Sorà F, Chiusolo P, Teofili L, Bacigalupo A, Sica S
Bone Marrow Transplant 2022 Apr;57(4):532-537. Epub 2022 Jan 22 doi: 10.1038/s41409-022-01574-0. PMID: 35066570
Cord blood chimerism and relapse after haplo-cord transplantation.
van Besien K, Koshy N, Gergis U, Mayer S, Cushing M, Rennert H, Reich-Slotky R, Mark T, Pearse R, Rossi A, Phillips A, Vasovic L, Ferrante R, Hsu YM, Shore T
Leuk Lymphoma 2017 Feb;58(2):288-297. Epub 2016 Jun 23 doi: 10.1080/10428194.2016.1190970. PMID: 27333804Free PMC Article

Therapy

Azacitidine, lenalidomide and donor lymphocyte infusions for relapse of myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia after allogeneic transplant: the Azalena-Trial.
Schroeder T, Stelljes M, Christopeit M, Esseling E, Scheid C, Mikesch JH, Rautenberg C, Jäger P, Cadeddu RP, Drusenheimer N, Holtick U, Klein S, Trenschel R, Haas R, Germing U, Kröger N, Kobbe G
Haematologica 2023 Nov 1;108(11):3001-3010. doi: 10.3324/haematol.2022.282570. PMID: 37259567Free PMC Article
Ikaros expression is associated with an increased risk of chronic graft-versus-host disease.
Pereira AD, de Molla VC, Fonseca ARBM, Tucunduva L, Novis Y, Pires MS, Popi AF, Arrais-Rodrigues CA
Sci Rep 2023 May 25;13(1):8458. doi: 10.1038/s41598-023-35609-3. PMID: 37231055Free PMC Article
Post-transplant cyclophosphamide as sole GHVD prophylaxis after matched reduced-intensity conditioning allotransplant.
Bourgeois AL, Jullien M, Garnier A, Peterlin P, Béné MC, Guillaume T, Chevallier P
Clin Transl Med 2023 Apr;13(4):e1242. doi: 10.1002/ctm2.1242. PMID: 37140099Free PMC Article
Low-dose antithymocyte globulin inhibits chronic graft-versus-host disease in peripheral blood stem cell transplantation from unrelated donors.
Shiratori S, Sugita J, Fuji S, Aoki J, Sawa M, Ozawa Y, Hashimoto D, Matsuoka KI, Imada K, Doki N, Ashida T, Ueda Y, Tanaka M, Sawayama Y, Ichinohe T, Terakura S, Morishima S, Atsuta Y, Fukuda T, Teshima T
Bone Marrow Transplant 2021 Sep;56(9):2231-2240. Epub 2021 May 7 doi: 10.1038/s41409-021-01314-w. PMID: 33963304
High-Dose Cyclophosphamide and Tacrolimus as Graft-versus-Host Disease Prophylaxis for Matched and Mismatched Unrelated Donor Transplantation.
Pedraza A, Jorge S, Suárez-Lledó M, Pereira A, Gutiérrez-García G, Fernández-Avilés F, Rosiñol L, Llobet N, Solano T, Urbano-Ispízua Á, Rovira M, Martínez C
Transplant Cell Ther 2021 Jul;27(7):619.e1-619.e8. Epub 2021 Mar 25 doi: 10.1016/j.jtct.2021.03.022. PMID: 33895157

Prognosis

Haploidentical bone marrow transplants with post transplant cyclophosphamide on day + 3 + 5: The Genova protocol.
Raiola AM, Angelucci E, Sica S, Bacigalupo A
Blood Rev 2023 Nov;62:101031. Epub 2022 Nov 11 doi: 10.1016/j.blre.2022.101031. PMID: 36435691
Age is no barrier for adults undergoing HCT for AML in CR1: contemporary CIBMTR analysis.
Maakaron JE, Zhang MJ, Chen K, Abhyankar S, Bhatt VR, Chhabra S, El Jurdi N, Farag SS, He F, Juckett M, de Lima M, Majhail N, van der Poel M, Saad A, Savani B, Ustun C, Waller EK, Litzow M, Kebriaei P, Hourigan CS, Saber W, Weisdorf D
Bone Marrow Transplant 2022 Jun;57(6):911-917. Epub 2022 Apr 2 doi: 10.1038/s41409-022-01650-5. PMID: 35368040Free PMC Article
Low-dose antithymocyte globulin inhibits chronic graft-versus-host disease in peripheral blood stem cell transplantation from unrelated donors.
Shiratori S, Sugita J, Fuji S, Aoki J, Sawa M, Ozawa Y, Hashimoto D, Matsuoka KI, Imada K, Doki N, Ashida T, Ueda Y, Tanaka M, Sawayama Y, Ichinohe T, Terakura S, Morishima S, Atsuta Y, Fukuda T, Teshima T
Bone Marrow Transplant 2021 Sep;56(9):2231-2240. Epub 2021 May 7 doi: 10.1038/s41409-021-01314-w. PMID: 33963304
Impact of anti-thymocyte globulin dose for graft-versus-host disease prophylaxis in allogeneic hematopoietic cell transplantation from matched unrelated donors: a multicenter experience.
Butera S, Cerrano M, Brunello L, Dellacasa CM, Faraci DG, Vassallo S, Mordini N, Sorasio R, Zallio F, Busca A, Bruno B, Giaccone L
Ann Hematol 2021 Jul;100(7):1837-1847. Epub 2021 May 4 doi: 10.1007/s00277-021-04521-z. PMID: 33948721Free PMC Article
Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse.
Lee SJ, Klein JP, Barrett AJ, Ringden O, Antin JH, Cahn JY, Carabasi MH, Gale RP, Giralt S, Hale GA, Ilhan O, McCarthy PL, Socie G, Verdonck LF, Weisdorf DJ, Horowitz MM
Blood 2002 Jul 15;100(2):406-14. doi: 10.1182/blood.v100.2.406. PMID: 12091329

Clinical prediction guides

Ikaros expression is associated with an increased risk of chronic graft-versus-host disease.
Pereira AD, de Molla VC, Fonseca ARBM, Tucunduva L, Novis Y, Pires MS, Popi AF, Arrais-Rodrigues CA
Sci Rep 2023 May 25;13(1):8458. doi: 10.1038/s41598-023-35609-3. PMID: 37231055Free PMC Article
Post-transplant cyclophosphamide as sole GHVD prophylaxis after matched reduced-intensity conditioning allotransplant.
Bourgeois AL, Jullien M, Garnier A, Peterlin P, Béné MC, Guillaume T, Chevallier P
Clin Transl Med 2023 Apr;13(4):e1242. doi: 10.1002/ctm2.1242. PMID: 37140099Free PMC Article
Haploidentical bone marrow transplants with post transplant cyclophosphamide on day + 3 + 5: The Genova protocol.
Raiola AM, Angelucci E, Sica S, Bacigalupo A
Blood Rev 2023 Nov;62:101031. Epub 2022 Nov 11 doi: 10.1016/j.blre.2022.101031. PMID: 36435691
Low-dose antithymocyte globulin inhibits chronic graft-versus-host disease in peripheral blood stem cell transplantation from unrelated donors.
Shiratori S, Sugita J, Fuji S, Aoki J, Sawa M, Ozawa Y, Hashimoto D, Matsuoka KI, Imada K, Doki N, Ashida T, Ueda Y, Tanaka M, Sawayama Y, Ichinohe T, Terakura S, Morishima S, Atsuta Y, Fukuda T, Teshima T
Bone Marrow Transplant 2021 Sep;56(9):2231-2240. Epub 2021 May 7 doi: 10.1038/s41409-021-01314-w. PMID: 33963304
High-Dose Cyclophosphamide and Tacrolimus as Graft-versus-Host Disease Prophylaxis for Matched and Mismatched Unrelated Donor Transplantation.
Pedraza A, Jorge S, Suárez-Lledó M, Pereira A, Gutiérrez-García G, Fernández-Avilés F, Rosiñol L, Llobet N, Solano T, Urbano-Ispízua Á, Rovira M, Martínez C
Transplant Cell Ther 2021 Jul;27(7):619.e1-619.e8. Epub 2021 Mar 25 doi: 10.1016/j.jtct.2021.03.022. PMID: 33895157

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...